The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
Administered orally
Administered orally
Clinical Pharmacology of Miami
Miami, Florida, United States
Axis
Dilworth, Minnesota, United States
Ohio Clinical Trials
Columbus, Ohio, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Percent Change from Baseline in Visceral Adipose Tissue (VAT)
Time frame: Baseline, Week 36
Percent Change from Baseline in Energy Intake
Time frame: Baseline, Week 36
Percent Change from Baseline in Appetite
Time frame: Baseline, Week 36
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 36
Percent Change from Baseline in Fasting Total Cholesterol
Time frame: Baseline, Week 36
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)
Time frame: Baseline, Week 36
Change from Baseline in International Physical Activity Questionnaire-Long Form (IPAQ-L) Scores
Time frame: Baseline, Week 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.